Patterns and determinants of COPD-related healthcare utilization by severity of airway obstruction in Korea

BMC Pulmonary Medicine

Table 2 Patterns of healthcare visits, PFTs, and prescribed medications according to severity of airflow obstruction

	Mild	Moderate	Severe
	No. (%)	No. (%)	No. (%)
	74 (30.3)	128 (52.5)	42 (17.2)	Pvalue
Healthcare visit (frequency/person/year)*
Total	2.014 ± 0.323	3.675 ± 0.473	5.764 ± 0.783	<0.001
Outpatient clinic	1.895 ± 0.325	3.594 ± 0.472	5.516 ± 0.732	<0.001
Inpatient clinic	0.118 ± 0.051	0.082 ± 0.021	0.248 ± 0.114	0.091
ICU	0.025 ± 0.020	0.005 ± 0.004	0.039 ± 0.024	0.219
ED	0.009 ± 0.007	0.023 ± 0.010	0.071 ± 0.049	0.124
PFT (frequency/person/year)*	0.109 ± 0.032	0.168 ± 0.025	0.263 ± 0.059	0.031
Medications (frequency/person/year)*
SABA	0.050 ± 0.026	0.287 ± 0.135	0.957 ± 0.290	0.003
SAMA	0.036 ± 0.023	0.036 ± 0.015	0.200 ± 0.104	0.012
LAMA	0.178 ± 0.163	0.213 ± 0.080	1.940 ± 0.492	<0.001
LABA+ICS	0.054 ± 0.046	0.408 ± 0.137	1.280 ± 0.395	<0.001
ICS	0.050 ± 0.045	0.032 ± 0.014	0.194 ± 0.107	0.051
Oral theophylline	0.484 ± 0.121	1.156 ± 0.254	3.162 ± 0.571	<0.001
Oral corticosteroid	0.143 ± 0.081	0.390 ± 0.116	1.422 ± 0.451	<0.001

*= mean ± standard error; ICU = intensive care unit; ED = emergency department; PFT = pulmonary function test; SABA = inhaled short-acting β agonist; SAMA = inhaled short-acting anticholinergic; LAMA = inhaled long-acting anticholinergic; LABA+ICS = inhaled long-acting β-agonist combined with corticosteroid; ICS = inhaled corticosteroid.

ISSN: 1471-2466